Day 3 Interview with KJ Lavan on the Confluence of Epigenetics, Plant Me...
KJ Lavan presents a high-level perspective on the synergy of mental health, longevity, & psychedelics and the consequential benefits it can have for the world.
Beyond Amyloid & Tau: Leveraging Molecular Subtypes and Repurposed Drugs for Personalized AD Treatment
CTAD 2024 Abstract Title : Beyon d Amyloi d & T au : Leveraging Molecular Subtypes and Repurposed Drugs for Personalized AD Treatment Au t hor : KJ Lavan , Brain Matrix Alliance, Dubai, UAE Background : Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Despite decades of research, there are currently only a handful of approved drugs, and none offer a cure. Traditional drug discovery for AD has a notoriously high 99% failure rate. This highlights the urgent need for new approaches. Stratified medicine, which tailors treatments to specific patient subgroups based on their unique molecular and genetic profiles, and drug repurposing, which leverages existing medications for new therapeutic uses, are emerging as promising strategies. Methods : While there are ongoing drug repurposing efforts in AD, these studies often target the entire patient population,...
Comments
Post a Comment